Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 45

1.

Compressive optic neuropathy secondary to an allergic reaction to hyaluronidase.

Alcubierre R, Sanchez-Dalmau BF, Mousavi K.

Arch Soc Esp Oftalmol. 2019 Jul 4. pii: S0365-6691(19)30119-4. doi: 10.1016/j.oftal.2019.03.017. [Epub ahead of print] English, Spanish.

PMID:
31280939
2.

Cockayne syndrome in adults: complete retinal dysfunction exploration of two case reports.

Figueras-Roca M, Budi V, Morató M, Camós-Carreras A, Muñoz JE, Sánchez-Dalmau B.

Doc Ophthalmol. 2019 Jun;138(3):241-246. doi: 10.1007/s10633-019-09681-y. Epub 2019 Feb 28.

PMID:
30820731
3.

Ocular surface adverse events of systemic epidermal growth factor receptor inhibitors (EGFRi): A prospective trial.

Saint-Jean A, Reguart N, Eixarch A, Adán A, Castellà C, Sánchez-Dalmau B, Sainz-de-la-Maza M.

J Fr Ophtalmol. 2018 Dec;41(10):955-962. doi: 10.1016/j.jfo.2018.07.005. Epub 2018 Nov 23.

PMID:
30473235
4.

Predictors of vision impairment in Multiple Sclerosis.

Sanchez-Dalmau B, Martinez-Lapiscina EH, Pulido-Valdeolivas I, Zubizarreta I, Llufriu S, Blanco Y, Sola-Valls N, Sepulveda M, Guerrero A, Alba S, Andorra M, Camos A, Sanchez-Vela L, Alfonso V, Saiz A, Villoslada P.

PLoS One. 2018 Apr 17;13(4):e0195856. doi: 10.1371/journal.pone.0195856. eCollection 2018.

5.

Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis.

Petzold A, Balcer LJ, Calabresi PA, Costello F, Frohman TC, Frohman EM, Martinez-Lapiscina EH, Green AJ, Kardon R, Outteryck O, Paul F, Schippling S, Vermersch P, Villoslada P, Balk LJ; ERN-EYE IMSVISUAL.

Lancet Neurol. 2017 Oct;16(10):797-812. doi: 10.1016/S1474-4422(17)30278-8. Epub 2017 Sep 12. Review.

PMID:
28920886
6.

Early retinal atrophy predicts long-term visual impairment after acute optic neuritis.

Sanchez-Dalmau B, Martinez-Lapiscina EH, Torres-Torres R, Ortiz-Perez S, Zubizarreta I, Pulido-Valdeolivas IV, Alba-Arbalat S, Guerrero-Zamora A, Calbet D, Villoslada P.

Mult Scler. 2018 Aug;24(9):1196-1204. doi: 10.1177/1352458517718628. Epub 2017 Jul 3.

PMID:
28669275
7.

Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders.

Martinez-Lapiscina EH, Sepulveda M, Torres-Torres R, Alba-Arbalat S, Llufriu S, Blanco Y, Guerrero-Zamora AM, Sola-Valls N, Ortiz-Perez S, Villoslada P, Sanchez-Dalmau B, Saiz A.

Ther Adv Neurol Disord. 2016 Sep;9(5):436-40. doi: 10.1177/1756285616655264. Epub 2016 Aug 15. No abstract available.

8.

Phenytoin for neuroprotection.

Martinez-Lapiscina EH, Andorra M, Sanchez-Dalmau B, Villoslada P.

Lancet Neurol. 2016 Aug;15(9):901-902. doi: 10.1016/S1474-4422(16)30093-X. No abstract available.

PMID:
27478946
9.

Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study.

Martinez-Lapiscina EH, Arnow S, Wilson JA, Saidha S, Preiningerova JL, Oberwahrenbrock T, Brandt AU, Pablo LE, Guerrieri S, Gonzalez I, Outteryck O, Mueller AK, Albrecht P, Chan W, Lukas S, Balk LJ, Fraser C, Frederiksen JL, Resto J, Frohman T, Cordano C, Zubizarreta I, Andorra M, Sanchez-Dalmau B, Saiz A, Bermel R, Klistorner A, Petzold A, Schippling S, Costello F, Aktas O, Vermersch P, Oreja-Guevara C, Comi G, Leocani L, Garcia-Martin E, Paul F, Havrdova E, Frohman E, Balcer LJ, Green AJ, Calabresi PA, Villoslada P; IMSVISUAL consortium.

Lancet Neurol. 2016 May;15(6):574-84. doi: 10.1016/S1474-4422(16)00068-5. Epub 2016 Mar 18.

PMID:
27011339
10.

Visual field impairment captures disease burden in multiple sclerosis.

Ortiz-Perez S, Andorra M, Sanchez-Dalmau B, Torres-Torres R, Calbet D, Lampert EJ, Alba-Arbalat S, Guerrero-Zamora AM, Zubizarreta I, Sola-Valls N, Llufriu S, Sepúlveda M, Saiz A, Villoslada P, Martinez-Lapiscina EH.

J Neurol. 2016 Apr;263(4):695-702. doi: 10.1007/s00415-016-8034-2. Epub 2016 Feb 9.

PMID:
26860093
11.

Color vision impairment in multiple sclerosis points to retinal ganglion cell damage.

Lampert EJ, Andorra M, Torres-Torres R, Ortiz-Pérez S, Llufriu S, Sepúlveda M, Sola N, Saiz A, Sánchez-Dalmau B, Villoslada P, Martínez-Lapiscina EH.

J Neurol. 2015 Nov;262(11):2491-7. doi: 10.1007/s00415-015-7876-3. Epub 2015 Aug 11.

PMID:
26259563
12.

Changes in macular layers in the early course of non-arteritic ischaemic optic neuropathy.

Keller J, Oakley JD, Russakoff DB, Andorrà-Inglés M, Villoslada P, Sánchez-Dalmau BF.

Graefes Arch Clin Exp Ophthalmol. 2016 Mar;254(3):561-7. doi: 10.1007/s00417-015-3066-3. Epub 2015 May 28.

PMID:
26016810
13.

Dynamics of retinal injury after acute optic neuritis.

Gabilondo I, Martínez-Lapiscina EH, Fraga-Pumar E, Ortiz-Perez S, Torres-Torres R, Andorra M, Llufriu S, Zubizarreta I, Saiz A, Sanchez-Dalmau B, Villoslada P.

Ann Neurol. 2015 Mar;77(3):517-28. doi: 10.1002/ana.24351. Epub 2015 Feb 14.

PMID:
25559267
14.

The multiple sclerosis visual pathway cohort: understanding neurodegeneration in MS.

Martínez-Lapiscina EH, Fraga-Pumar E, Gabilondo I, Martínez-Heras E, Torres-Torres R, Ortiz-Pérez S, Llufriu S, Tercero A, Andorra M, Roca MF, Lampert E, Zubizarreta I, Saiz A, Sanchez-Dalmau B, Villoslada P.

BMC Res Notes. 2014 Dec 15;7:910. doi: 10.1186/1756-0500-7-910.

15.

Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis.

Llufriu S, Sepúlveda M, Blanco Y, Marín P, Moreno B, Berenguer J, Gabilondo I, Martínez-Heras E, Sola-Valls N, Arnaiz JA, Andreu EJ, Fernández B, Bullich S, Sánchez-Dalmau B, Graus F, Villoslada P, Saiz A.

PLoS One. 2014 Dec 1;9(12):e113936. doi: 10.1371/journal.pone.0113936. eCollection 2014.

16.

Treatment of acute optic neuritis and vision complaints in multiple sclerosis.

Torres-Torres R, Sanchez-Dalmau BF.

Curr Treat Options Neurol. 2015 Jan;17(1):328. doi: 10.1007/s11940-014-0328-z.

PMID:
25399875
17.

Multidisciplinary management of multiple sclerosis symptoms.

Gallien P, Gich J, Sánchez-Dalmau BF, Feneberg W.

Eur Neurol. 2014;72 Suppl 1:20-5. doi: 10.1159/000367620. Epub 2014 Sep 26.

18.

The visual pathway as a model to understand brain damage in multiple sclerosis.

Martínez-Lapiscina EH, Sanchez-Dalmau B, Fraga-Pumar E, Ortiz-Perez S, Tercero-Uribe AI, Torres-Torres R, Villoslada P.

Mult Scler. 2014 Nov;20(13):1678-85. doi: 10.1177/1352458514542862. Epub 2014 Jul 10. Review.

PMID:
25013155
19.

Lesions in the posterior visual pathway promote trans-synaptic degeneration of retinal ganglion cells.

Keller J, Sánchez-Dalmau BF, Villoslada P.

PLoS One. 2014 May 23;9(5):e97444. doi: 10.1371/journal.pone.0097444. eCollection 2014.

20.

Is the incidence of optic neuritis rising? Evidence from an epidemiological study in Barcelona (Spain), 2008-2012.

Martínez-Lapiscina EH, Fraga-Pumar E, Pastor X, Gómez M, Conesa A, Lozano-Rubí R, Sánchez-Dalmau B, Alonso A, Villoslada P.

J Neurol. 2014 Apr;261(4):759-67. doi: 10.1007/s00415-014-7266-2. Epub 2014 Feb 16.

PMID:
24532201

Supplemental Content

Loading ...
Support Center